Sundeep Agrawal

1.1k total citations · 1 hit paper
34 papers, 664 citations indexed

About

Sundeep Agrawal is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Sundeep Agrawal has authored 34 papers receiving a total of 664 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 13 papers in Surgery and 13 papers in Oncology. Recurrent topics in Sundeep Agrawal's work include Cancer Genomics and Diagnostics (11 papers), Renal cell carcinoma treatment (9 papers) and Bladder and Urothelial Cancer Treatments (7 papers). Sundeep Agrawal is often cited by papers focused on Cancer Genomics and Diagnostics (11 papers), Renal cell carcinoma treatment (9 papers) and Bladder and Urothelial Cancer Treatments (7 papers). Sundeep Agrawal collaborates with scholars based in United States, Germany and Tunisia. Sundeep Agrawal's co-authors include Daniel J. Sucato, Richard Pazdur, Shenghui Tang, Daniel L. Suzman, Amna Ibrahim, Paul G. Kluetz, Laleh Amiri‐Kordestani, Julia A. Beaver, Michael O’Brien and Thomas G. Lowe and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Journal of Bone and Joint Surgery.

In The Last Decade

Sundeep Agrawal

30 papers receiving 648 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

2022 127 citations Jaleh Fallah, Sundeep Agrawal et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sundeep Agrawal United States	11	325	236	179	98	85	34	664
Che‐Kai Tsao United States	15	253 0.8×	260 1.1×	356 2.0×	58 0.6×	158 1.9×	80	769
Renjian Jiang United States	16	209 0.6×	406 1.7×	220 1.2×	55 0.6×	61 0.7×	61	689
Yongrui Bai China	14	191 0.6×	278 1.2×	244 1.4×	116 1.2×	181 2.1×	49	739
Michal Sarfaty Israel	13	149 0.5×	290 1.2×	182 1.0×	85 0.9×	74 0.9×	46	539
Emma Link Australia	16	309 1.0×	296 1.3×	230 1.3×	91 0.9×	256 3.0×	54	930
Virginia Arrazubi Spain	12	155 0.5×	372 1.6×	235 1.3×	33 0.3×	136 1.6×	48	641
Oyewale O. Abidoye United States	13	158 0.5×	451 1.9×	221 1.2×	53 0.5×	143 1.7×	24	657
Alyssa Klein United States	11	155 0.5×	331 1.4×	372 2.1×	49 0.5×	180 2.1×	28	754
Annalisa Garbi Italy	16	247 0.8×	251 1.1×	132 0.7×	32 0.3×	158 1.9×	37	1.0k
Earle F. Burgess United States	15	392 1.2×	274 1.2×	167 0.9×	22 0.2×	220 2.6×	68	700

Countries citing papers authored by Sundeep Agrawal

Since Specialization

Citations

This map shows the geographic impact of Sundeep Agrawal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sundeep Agrawal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sundeep Agrawal more than expected).

Fields of papers citing papers by Sundeep Agrawal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sundeep Agrawal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sundeep Agrawal. The network helps show where Sundeep Agrawal may publish in the future.

Co-authorship network of co-authors of Sundeep Agrawal

This figure shows the co-authorship network connecting the top 25 collaborators of Sundeep Agrawal. A scholar is included among the top collaborators of Sundeep Agrawal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sundeep Agrawal. Sundeep Agrawal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chang, Elaine, Haley Gittleman, Erik Bloomquist, et al.. (2025). The Food and Drug Administration pooled analysis of overall survival according to depth of response in frontline advanced immune-oncology renal cell carcinoma trials. JNCI Cancer Spectrum. 9(4).

Fallah, Jaleh, Jianjin Xu, Chana Weinstock, et al.. (2024). Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis. Journal of Clinical Oncology. 42(14). 1687–1698. 33 indexed citations

Maguire, William F., Daniel Lee, Chana Weinstock, et al.. (2024). FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma. Clinical Cancer Research. 30(10). 2011–2016. 13 indexed citations

Agrawal, Sundeep, William F. Pierce, Melanie Royce, et al.. (2024). FDA Approval Summary: Capecitabine Labeling Update under Project Renewal. Clinical Cancer Research. 30(24). 5508–5514.

Chang, Elaine, Chi Song, Haley Gittleman, et al.. (2024). A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma. Clinical Cancer Research. 30(15). 3282–3286. 5 indexed citations

Fallah, Jaleh, Jianjin Xu, Hee‐Koung Joeng, et al.. (2024). False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring ATM and CHEK2 Mutations. JCO Precision Oncology. 8(8). e2400354–e2400354.

Chang, Elaine, Haley Gittleman, Erik Bloomquist, et al.. (2023). FDA pooled analysis of overall survival according to depth of response as a continuous variable in frontline advanced immuno-oncology renal cell carcinoma trials.. Journal of Clinical Oncology. 41(16_suppl). e16532–e16532.

Chang, Elaine, Chi Young Song, Haley Gittleman, et al.. (2023). FDA analysis of treatment-free survival in frontline advanced immuno-oncology–VEGF TKI renal cell carcinoma trials.. Journal of Clinical Oncology. 41(16_suppl). e13602–e13602. 2 indexed citations

Lee, Daniel, Haley Gittleman, Chana Weinstock, et al.. (2023). A U.S. Food and Drug Administration–pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma. European Urology. 84(4). 373–378. 8 indexed citations

10.

Fallah, Jaleh, Sundeep Agrawal, Haley Gittleman, et al.. (2022). FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 29(9). 1651–1657. 127 indexed citations breakdown →

11.

Agrawal, Sundeep, Shaily Arora, Laleh Amiri‐Kordestani, et al.. (2022). Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021. JAMA Oncology. 9(2). 266–266. 43 indexed citations

12.

Rivera, Donna R., Paul G. Kluetz, Sundeep Agrawal, et al.. (2022). Clinical Evidence Generation During a Pandemic. The Cancer Journal. 28(2). 151–156. 2 indexed citations

13.

Cheng, Connie, et al.. (2021). Arterial aneurysm and dissection with systemic vascular endothelial growth factor inhibitors: A review of cases reported to the FDA Adverse Event Reporting System and published in the literature. Vascular Medicine. 26(5). 526–534. 12 indexed citations

14.

Kluetz, Paul G., Patricia Keegan, George D. Demetri, et al.. (2020). FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs. Clinical Cancer Research. 27(4). 916–921. 8 indexed citations

15.

Weinstock, Chana, Laura L. Fernandes, Elaine Chang, et al.. (2020). Impact of timing of antibiotic use on clinical outcomes in patients with urothelial cancer treated with immune checkpoint inhibitors (ICIs).. Journal of Clinical Oncology. 38(15_suppl). 5045–5045. 2 indexed citations

16.

Brewer, Jamie R., Elaine Chang, Sundeep Agrawal, et al.. (2020). Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case Studies. Clinical Cancer Research. 26(24). 6406–6411. 6 indexed citations

17.

Weinstock, Chana, V. Ellen Maher, Laura L. Fernandes, et al.. (2019). An FDA analysis of the association between adverse events and outcome in patients with urothelial cancer receiving a programmed death protein 1 or programmed death ligand 1 (anti-PD-1/L1) antibody.. Journal of Clinical Oncology. 37(15_suppl). 4549–4549. 1 indexed citations

18.

Suzman, Daniel L., Sundeep Agrawal, V. Ellen Maher, et al.. (2018). FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy. The Oncologist. 24(4). 563–569. 138 indexed citations

19.

Ranpura, Vishal, Sundeep Agrawal, Charan Yerasi, et al.. (2015). Improving Documentation of Pain Management at MedStar Washington Cancer Institute. Journal of Oncology Practice. 11(2). 155–157. 11 indexed citations

20.

Sucato, Daniel J., et al.. (2008). Postoperative Ketorolac Does Not Predispose to Pseudoarthrosis Following Posterior Spinal Fusion and Instrumentation for Adolescent Idiopathic Scoliosis. Spine. 33(10). 1119–1124. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact